Please wait while the formulary information is being retrieved.
PANTOPRAZOLE SODIUM (PANTOPRAZOLE SODIUM)
- Erosive esophagitis
- Gastric hypersecretion with systemic mastocytosis
- Gastroesophageal reflux disease
- Maintenance of healing erosive esophagitis
- Pathological gastric acid hypersecretory condition
- Zollinger-ellison syndrome
- Protonix Tablet,delayed Release
- Protonix Intravenous Solution
- Pantoprazole Tablet,delayed Release
- Pantoprazole Intravenous Solution
- By Indication
20 mg tablet,delayed release
- 2 tablets (40 mg) by oral route once daily
40 mg tablet,delayed release
- 1 tablet (40 mg) by oral route once daily
Protonix 40 mg intravenous solution
- Infuse 40 mg by intravenous route once daily
20 mg tablet,delayed release
- 2 tablets (40 mg) by oral route once daily
40 mg tablet,delayed release
- 1 tablet (40 mg) by oral route once daily
pantoprazole 20 mg tablet,delayed release
- 2 tablets (40 mg) by oral route once daily
pantoprazole 40 mg tablet,delayed release
- 1 tablet (40 mg) by oral route once daily
40 mg intravenous solution
- Infuse 40 mg by intravenous route once daily
pantoprazole 40 mg intravenous solution
- Infuse 40 mg by intravenous route once daily
Erosive esophagitis
- Infuse 40 mg over by intravenous route once daily for 10 days
- Infuse 40 mg by intravenous route once daily
- 2 tablets (40 mg) by oral route once daily
- 1 tablet (40 mg) by oral route once daily
Gastric hypersecretion with systemic mastocytosis
- Infuse 80 mg by intravenous route every 8 hours
- Infuse 80 mg by intravenous route every 12 hours
- 2 tablets (40 mg) by oral route 2 times per day
- 1 tablet (40 mg) by oral route 2 times per day
- 3 tablets (60 mg) by oral route 2 times per day
- 2 tablets (80 mg) by oral route 2 times per day
- 3 tablets (120 mg) by oral route 2 times per day
Gastroesophageal reflux disease
- Infuse 40 mg over by intravenous route once daily for 7 days
- Infuse 40 mg over by intravenous route once daily for 10 days
- Infuse 40 mg by intravenous route once daily
- Infuse 20 mg by intravenous route once daily
- 1 tablet (20 mg) by oral route once daily
- 2 tablets (40 mg) by oral route once daily
- 1 tablet (40 mg) by oral route once daily
- 2 tablets (40 mg) by oral route once daily for 8 weeks
- 1 tablet (40 mg) by oral route once daily for 8 weeks
Maintenance of healing erosive esophagitis
- 2 tablets (40 mg) by oral route once daily
Pathological gastric acid hypersecretory condition
- 2 tablets (40 mg) by oral route 2 times per day
- 1 tablet (40 mg) by oral route 2 times per day
- 3 tablets (60 mg) by oral route 2 times per day
- 2 tablets (80 mg) by oral route 2 times per day
- 3 tablets (120 mg) by oral route 2 times per day
Zollinger-ellison syndrome
- Infuse 80 mg by intravenous route every 8 hours
- Infuse 80 mg by intravenous route every 12 hours
- 2 tablets (40 mg) by oral route 2 times per day
- 1 tablet (40 mg) by oral route 2 times per day
- 3 tablets (60 mg) by oral route 2 times per day
- 2 tablets (80 mg) by oral route 2 times per day
- 3 tablets (120 mg) by oral route 2 times per day
- atazanavir
- Complera
- Edurant
- emtricitab-rilpivirine-tenofov
- nelfinavir
- Reyataz
- rilpivirine
- Viracept
Contraindicated
- Bosulif
- bosutinib
- Cellcept
- Cellcept Intravenous
- dasatinib
- erlotinib
- itraconazole
- ketoconazole
- methotrexate sodium
- methotrexate sodium (PF)
- mycophenolate mofetil
- mycophenolate mofetil HCl
- nilotinib
- Noxafil
- Onmel
- posaconazole
- Sporanox
- Sporanox Pulsepak
- Sprycel
- Tarceva
- Tasigna
Severe
Moderate
- Adderall
- Adderall Xr
- Amphetamine Salt Combo
- Ceftin
- cefuroxime axetil
- Dexedrine Spansule
- dextroamphetamine
- dextroamphetamine-amphetamine
- Isentress
- Methotrexate (anti-rheumatic)
- Procentra
- raltegravir
- Rheumatrex
- Trexall
- Zenzedi
- None
Contraindicated
- Clostridium difficile infection
- Interstitial nephritis
- Subacute cutaneous lupus erythematosus
- Systemic lupus erythematosus
Severe
Moderate
- CYp2c19 poor metabolizer
- Fracture
- Hypomagnesemia
- Osteoporosis
- Vitamin b12 deficiency
PANTOPRAZOLE SODIUM (PANTOPRAZOLE SODIUM)
- Erosive esophagitis
- Gastric hypersecretion with systemic mastocytosis
- Gastroesophageal reflux disease
- Maintenance of healing erosive esophagitis
- Pathological gastric acid hypersecretory condition
- Zollinger-ellison syndrome
- None
- Abdominal pain with cramps
- Acute abdominal pain
- Arthralgias
- Diarrhea
- Dizziness
- Flatulence
- Headache disorder
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- None
- Malaise
- Skin rash
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute hepatic failure
- Agranulocytosis
- Anaphylaxis
- Angioedema
- Atrophic gastritis
- Bronchospastic pulmonary disease
- Clostridium difficile infection
- Depression
- Erythema multiforme
- Exfoliative dermatitis
- Facial edema
- Fracture
- Hepatic failure
- Hepatitis
- Hepatocellular damage
- Hypertriglyceridemia
- Hyponatremia
- Increased creatine kinase level
- Injection site sequelae
- Interstitial nephritis
- Jaundice
- Leukopenia
- Neutropenic disorder
- Pancytopenia
- Rhabdomyolysis
- Stevens-johnson syndrome
- Subacute cutaneous lupus erythematosus
- Systemic lupus erythematosus
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
Less Severe
- Acute confusion
- Benign fundic gland polyposis of stomach
- Blurred vision
- Constipation
- Drowsy
- Dysgeusia
- Fatigue
- General weakness
- Hallucinations
- Hypercholesterolemia
- Hypertriglyceridemia
- Hypomagnesemia
- Increased urinary frequency
- Insomnia
- Loss of taste
- Malaise
- Myalgias
- Nausea
- Pain
- Pruritus of skin
- Rhinitis
- Skin photosensitivity
- Skin rash
- Thrombophlebitis
- Upper respiratory infection
- Urticaria
- Vertigo
- Vitamin b12 deficiency
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Pantoprazole (IV)
Safety and efficacy of intravenous formulation not established.
Efficacy not established age <1 year.
Delayed release formulations may not be appropriate for age range dosing depending on indication for use.
- 1 Day – 18 Years
- Safety and efficacy of intravenous formulation not established.
- 1 Day – 364 Days
- Safety and efficacy of intravenous formulation not established.
- 1 Years – 5 Years
- Safety and efficacy of intravenous formulation not established.
Pantoprazole (Oral)
Safety and efficacy of intravenous formulation not established.
Efficacy not established age <1 year.
Delayed release formulations may not be appropriate for age range dosing depending on indication for use.
- 1 Day – 18 Years
- Efficacy not established age <1 year.
- Delayed release formulations may not be appropriate for age range dosing depending on indication for use.
- 1 Day – 364 Days
- Efficacy not established age <1 year.
- Delayed release formulations may not be appropriate for age range dosing depending on indication for use.
- 1 Years – 5 Years
- Efficacy not established age <1 year.
- Delayed release formulations may not be appropriate for age range dosing depending on indication for use.
Pantoprazole
- Severity Level:
2
- Additional Notes: Available human data show no increased risk for major birth defects.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Pantoprazole
Limited data suggest low amounts excreted with no known adverse infant effect
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest low amounts excreted with no known adverse infant effect |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Pantoprazole (oral)
General-Prolonged use may dec absorption of Vitamin B-12. Avoid for >8 weeks duration unless for high risk patients (eg. oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett's esophagitis, pathologic hypersecretory condition, or demonstrated need for maint treatment. Musculoskeletal-Inc risk of fracture with high dose or use >1 year. Gastrointestinal-Long term use may be assoc w/ C. difficile or GI malignancy. Pulmonary-Long term use may be assoc w/ pneumonia.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | Y | N |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- None
| Erosive esophagitis | |
| K22.1 | Ulcer of esophagus |
| K22.10 | Ulcer of esophagus without bleeding |
| K22.11 | Ulcer of esophagus with bleeding |
| Gastric hypersecretion with systemic mastocytosis | |
| C96.21 | Aggressive systemic mastocytosis |
| D47.02 | Systemic mastocytosis |
| K31.89 | Other diseases of stomach and duodenum |
| Gastroesophageal reflux disease | |
| K21 | Gastro-esophageal reflux disease |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| Maintenance of healing erosive esophagitis | |
| K22.1 | Ulcer of esophagus |
| K22.10 | Ulcer of esophagus without bleeding |
| K22.11 | Ulcer of esophagus with bleeding |
| Pathological gastric acid hypersecretory condition | |
| K31.89 | Other diseases of stomach and duodenum |
| Zollinger-ellison syndrome | |
| E16.4 | Increased secretion of gastrin |
| 0-9 | A-Z |
|---|---|
| C96.21 | Aggressive systemic mastocytosis |
| D47.02 | Systemic mastocytosis |
| E16.4 | Increased secretion of gastrin |
| K21 | Gastro-esophageal reflux disease |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| K22.1 | Ulcer of esophagus |
| K22.1 | Ulcer of esophagus |
| K22.10 | Ulcer of esophagus without bleeding |
| K22.10 | Ulcer of esophagus without bleeding |
| K22.11 | Ulcer of esophagus with bleeding |
| K22.11 | Ulcer of esophagus with bleeding |
| K31.89 | Other diseases of stomach and duodenum |
| K31.89 | Other diseases of stomach and duodenum |
Formulary Reference Tool